Venetoclax is a clinically established BCL‐2 targeting BH3‐mimetic that has FDA approval for use in CLL patients with a 17p deletion and in combination with low‐dose cytarabine or hypomethylating agents, in the treatment of AML [20, 21, 22, 23]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.